Nasdaq.comUS
Edesa Biotech, Inc. Announces EU Orphan Designation for Paridiprubart
On November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute…